Abstract
PTC Therapeutics has agreed to acquire the Duchenne muscular dystrophy (DMD) treatment Emflaza from Marathon Pharmaceuticals for $140 million plus potential milestone payments. Marathon won FDA approval for Emflaza on Feb. 9 and immediately stirred controversy by pricing it at $89,000 per year, even though it is based on the generic steroid deflazacort. The firm subsequently paused the launch. PTC, which already markets the DMD treatment ataluren in Europe, says it is finalizing commercialization plans.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
